Leucémie lymphoïde chronique et anxiété : « surveiller et continuer à vivre » plutôt qu’« observer et attendre »

Nanette Cox-Kennett

Abstract


La leucémie lymphoïde chronique (LLC) est l’hémopathie maligne la plus courante. La majorité des personnes qui reçoivent un diagnostic de LLC entrent dans l’étape du suivi consistant à observer l’évolution de la maladie et à attendre. Cela peut donner l’impression d’avoir une épée de Damoclès au-dessus de la tête, mais le fait est que 30 % des personnes atteintes n’auront jamais besoin de traitement. Étant étroitement surveillés, les patients se disent anxieux, désemparés et déprimés. En effet, nous savons peu de choses sur l’expérience de ces patients et sur les interventions visant à adoucir leur parcours (Damen, 2022). Voulant « faire quelque chose », ils peuvent être tentés par des thérapies alternatives coûteuses et non éprouvées. Chaque visite en clinique est une occasion de donner au patient des informations pertinentes et compréhensibles, des ressources pour gérer l’anxiété et des réponses aux besoins non satisfaits; on l’aide ainsi à partager la prise de décisions. Pour la suite des choses, la perspective de « surveiller et continuer à vivre » au lieu d’« observer et attendre » peut aider les personnes atteintes de LLC à mieux vivre cette épreuve. 

 


Full Text:

PDF

References


Association Community Cancer Centers. (2022). Are we speaking the same language: Insight from a patient and provider survey on CLL. https://www.accc-cancer.org/docs/projects/chronic-lymphocytic-leukemia-(cll)/cll_survey_insights-2022.pdf

Baron, B. W., Thirman, M. J., Giurcanu, M. C., & Baron, J. M. (2018). Quercetin therapy for selected patients with PIM1 kinase-positive chronic lymphocytic leukemia/small lymphocytic lymphoma: A pilot study. Acta Haematologica, 139 (2), 132–139. https://doi.org/10.1159/000486361

Binet, JL., Auquier, A., Dighiero, G., Chastang, C., Piguest, H., Goasguen, J., Vaugier, G., Potrin, G., Colona, P., Oberling, F., Thomas, M., Tcherina, G., Jacquillat, C., Boivin, P., Lesty, C., Duault, M. T., Monconduit, M., Belabbes, S., & Gremy, F. (1981). A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 48(1), 198–206. https://doi.org/10.1002/1097-0142(19810701)48:1%3C198::aid-cncr2820480131%3E3.0.co;2-v

Da Cunha-Bang, C., Simonsen, J., Rostgaard, K., Geisler, C., Hjalgrim, H., & Niemann, C. U. (2016). Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: A Danish population – based study of 10455 patients. Blood Cancer, 6(11), e499. https://doi.org/10.1038/bcj.2016.105

Damen, M. D. C., Westerweel, P. E., Levin, M. D., & Pelle, A. J. (2022). Unmet supportive care needs, anxiety and depression in haematology patients during watch-and-wait. Psychooncology, 31(2), 176–184. https://doi.org/10.1002/pon.5800

D’Arena, G., Laurenti, L., Coscia, M., Cortelezzi, A., Chiarenza, A., Pozzato, G., Vigliotti, M. L., Nunziata, G., Fragasso, A., Villa, M. R., Grossi, A., Selleri, C., Deaglio, S., La Sala, A., Del Poeta, G., Simeon, V., Aliberti, L., De Martino, L., Giudice, A., Musto, P., De Feo, V. (2014). Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey. Leukemia & Lymphoma, 55(4), 841–847. https://doi.org/10.3109/10428194.2013.803223

Eichhorst, B., Niemann, C. U., Kater, A. P., Furstenau, M., von Tresckow, J., Zhang, C., Robrecht, S., Gregor, M., Juliusson, G., Thornton, P., Staber, P. B., Tadmor, T., Lindstrom, V., da Cunha-Bang, C., Schneider, C., Poulsen, C. B., Illmer, T., Schottker, B., Nosslinger, T., … & Hallek, M. (2023). First-line venetoclax combinations in chronic lymphocytic leukemia. The New England Journal of Medicine, 388, 1739-1754. https://doi.org//10.1056/NEJMoa2213093

Fischer, K., Bahlo, J., Fink, A. M., Goede, V., Herling, C. D., Cramer, P., Langerbeins, P., von Tresckow, J., Engelke, A., Maurer, C., Kovacs, G., Herling, M., Tausch, E., Kreuzer, K.-A., Eichhorst, B., Böttcher, S., Seymour, J. F., Ghia, P., Marlton, P., … & Hallek, M. (2016). Long- term remission after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trail. Blood, 127(2), 208–215. https://doi.org/10.1182/blood-2015-06-651125

Ghia, P., Owen, C., Barrientos, J. C., Barr, P. M., Mato, A. R., Shi, C., Szoke, A., Abbazio, C., Krigsfeld, G. S., & Burger, J. A. (2022). Initiating first-line (1L) Ibrutinib (Ibr) in patients (pts) with chronic lymphocytic leukemia (CLL) improves overall survival (OS), outcomes to rates approximating an age-matched population of ≥ 65 years. Blood, 140(1), 4159-4161. https://doi.org/10.1182/blood-2022-163257

Golombick, T., Diamond, T. H., Manoharan, A., & Ramakrishna, R. (2015). The effect of curcumin (as Meriva) on absolute lymphocyte count (ALC), NK cells and T cell populations in patients with stage 0/1 chronic lymphocytic leukemia. Journal of Cancer Therapy, 6 (7), 566–571. http://dx.doi.org/10.4236/jct.2015.67061

Government of Canada. (2017, November 15). Summary of safety review- green tea extract – containing natural health products – assessing the potential risk of liver injury (hepatotoxicity). https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/green-tea-extract-containing-natural-health-products-assessing-potential-risk-liver-injury.html

Guieze, R., & Wu, C. J. (2015). Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood, 126(4), 445–453. https://doi.org/10.1182/blood-2015-02-585042

Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M., Montserrat, E., Chiorazzi, N., Stilgenbauer, S., Rai, K. R., Byrd, J. C., Eichhorst, B., O’Brien, S., Robak, T., Seymour, J. F., & Kipps, T. J. (2018). iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood, 131(25), 2745–2760. https://doi.org/10.1182/blood-2017-09-806398

Kleinstern, G., O’Brein, D. R., Li, X., Tian, S., Kabat, B. F., Rabe, K. G., Norman, A. D., Yan, H., Vachon, C. M., Boddicker, N. J., Call, T. G., Parikh, S. A., Bruins, L., de Campos, C. B., Leis, J. F., Shanafelt, T. D., Ding, W., Cerhan, J. R., Kay, N. E., … & Braggio, E. (2020). Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index. American Journal of Hematology, 95(8), 906–917. https://doi.org/10.1002%2Fajh.25831

Molica, S., Shanafelt, T. D., Giannarelli, D., Gentile, M., Mirabelli, R., Cutrona, G., Levato, L., Renzo, N. D., Raimondo, F. D., Musolino, C., Angrilli, F., Famà , A., Recchia, A. G., Chaffee, K. G., Neri, A., Kay, N. E., Ferrarini, M., & Morabito, F. (2016). The chronic lymphocytic leukemia international prognostic index predicts time of first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. American Journal of Hematology, 91(11), 1090-1095. https://doi.org/10.1002/ajh.24493

Owen, C., Gerrie, A. S., Banerji, V., Assouline, S., Chen, C., Robinson, K. S., Lye, E., & Fraser, G. (2018). Canadian evidence-based guidelines for the first-line treatment of chronic lymphocytic leukemia. Current Oncology, 25(5), 461–474. https://doi.org/10.3747/co.25.4092

Parikh, A. S., Rabe, K. G., Kay, N. E., Call, T. G., Ding, W., Leis, J. F., Kenderian, S. S., Muchtar, E., Wang, Y., Koehler, A. B., Schwager, S. M., Lesnick, C. E., Klienstern, G., Dyke, D. V., Hanson, C. A., Braggio, E., Slager, S. L., & Shanafelt, T. D. (2021). The CLL international prognostic index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. Blood, 138(2), 149-159. https://doi.org/10.1182/blood.2020009813

Rai, K. R., Sawitsky, A., Cronkite, E. P., Chanana, A. D., Levy, R. N., & Pasternack, B. S. (1975). Clinical staging of chronic lymphocytic leukemia. Blood, 46(2), 219-234. https://doi.org/10.1182/blood-2016-08-737650

Rassenti, L. Z., Jain, S., Keating, M. J., Wierda, W. G., Grever, M. R., Byrd, J. C., Kay, N. E., Brown, J. R., Gribben, J. G., Neuberg, D. S., He, F., Greaves, A. W., Rai, K. R., & Kipps, T., J. (2008). Relative value of ZAP-70, CD38, and immunoglobin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood, 112(5), 1923–1930. https://doi.org/10.1182/blood-2007-05-092882

Rocque, G., Williams, C., Halilova, K., Borate, U., Jackson, B., Van Laar, E., Pisu, B., Butler, T., Davis, R., Mehta, A., Knight, S., & Safford, M. (2018). Improving shared decision-making in chronic lymphocytic leukemia through multidisciplinary education. Translational Behavioral Medicine, 8(2), 175–182. https//doi.org/10.1093/tbm/ibx034

Rojas-Gil, A. P., Kodonis, I., Ioannidis, A., Nomikos, T., Dimopoulos, I., Kosmidis, G., Katsa, M. E., Melliou, E., & Magiatis P. (2022). The effect of dietary intervention with high-oleocanthal and oleacein olive oil in patients with early-stage chronic lymphocytic leukemia: A pilot randomized trial. Frontiers in Oncology, 11, 810249. https://doi.org/10.3389/fonc.2021.810249

Sfeir, J. G., Drake, M. T., LaPlant, B. R., Maurer, M. J., Link, B. K., Berndt, T. J., Shanafelt, T. D., Cerhan, J. R., Habermann, T. M., Feldman, A. L., & Witzig, T. (2017). Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemia. Blood Cancer Journal, 7(2), e526. https://doi.org/10.1038/bcj.2017.9

Shanafelt, T. D., Bowen, D., Venkat, C., Slager, S. L., Zent, C. S., Kay, N. E., Reinalda, M., Sloan, J. A., & Call, T. G. (2007). Quality of life in chronic lymphocytic leukemia: A international survey of 1482 patients. British Journal of Hematology, 139(2), 255–264. https://doi.org/10.1111/j.1365-2141.2007.06791.x

Shanafelt, T. D., Call, T. G., Zent, C. S., Leis, J. F., Laplant, B., Bowen, D. A., Roos, M., Laumann, K., Ghosh, A. K., Lesnick, C., Lee, M. J., Yang, C. S., Jelinek, D. F., Erlichman, C., & Kay, N. E. (2013). Phase 2 trial of daily, oral polyphenon e in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer, 119(2), 363–370. https://doi.org/10.1002/cncr.27719

Sharman, J. P., Egyed, M., Jurczak, W., Skarbnik, A., Pagel, J. M., Flinn, I. W., Kamdar, M., Munir, T., Walewska, R., Corbett, G., Fogliatto, L. M., Herishanu, Y., Banjeri, V., Coutre, S., Follows, G., Walker, P., Karlsson, K., Chia, P., Janssens, A., … & Byrd, J. C. (2022). Efficacy and safety in a 4-year-follow-up of the ELEVATE-TN study comparing acalabrutinib with or without Obinutuzumab versus Obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia, 36(4), 1171–1175. https://doi.org/10.1038/s41375-021-01485-x

Statistics Canada. (2023, May 16). Number and rates of new cases of primary cancer, by cancer type, age group and sex. https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310011101


Refbacks

  • There are currently no refbacks.


Bookmark and Share